Disulfiram for Preventing Treatment Complications in Patients Undergoing CAR T-cell Therapy for Relapsed or Refractory Diffuse Large B-cell Lymphoma
NCT07932730, Phase 1, Phase 2, Not yet recruiting, University of Michigan Rogel Cancer Center
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Disulfiram for Preventing Treatment Complications in Patients Undergoing CAR T-cell Therapy for Relapsed or Refractory Diffuse Large B-cell Lymphoma | ClinicalTrials.gov |
| NCT number | NCT07932730 | ClinicalTrials.gov |
| Status | Not yet recruiting | ClinicalTrials.gov |
| Phases | Phase 1, Phase 2 | ClinicalTrials.gov |
| Enrollment | 12 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | University of Michigan Rogel Cancer Center | ClinicalTrials.gov |
| Conditions | Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | ClinicalTrials.gov |
| Interventions | Axicabtagene Ciloleucel, Biospecimen Collection, Computed Tomography, Cyclophosphamide, Disulfiram, Fludarabine, Positron Emission Tomography | ClinicalTrials.gov |
| First posted | 2026-11-12 | ClinicalTrials.gov |
| Last updated | 2026-11-12 | ClinicalTrials.gov |
Registered outcomes 6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Incidence of dose-limiting toxicities | Within day +35 post-chimeric antigen receptor (CAR) T-cell therapy | At the end of the trial, will report number of patients assigned to each dose, as well as the number of patients experiencing toxicity at each dose. | ClinicalTrials.gov |
| Primary | Proportion of patients that are alive and free from grade 2-4 cytokine release syndrome (CRS) with no intervening treatment of CRS | Through day +28 post-CAR T-cell therapy | At the end of the trial, will report number of patients assigned to each dose, as well as the number of patients experiencing efficacy outcomes at each dose. | ClinicalTrials.gov |
| Secondary | Incidence of grade 2-4 CRS | By day +28 post-CAR T-cell therapy | The occurrence of severe CRS will be considered binary, and the rate will be defined as number of patients with severe CRS divided by the number of evaluable patients. The rate will be reported along with the 95% exact binomial confidence interval. | ClinicalTrials.gov |
| Secondary | Incidence of all-grade CRS | By day +28 post-CAR T-cell therapy | The occurrence of CRS will be considered binary, and the rate will be defined as number of patients with CRS divided by the number of evaluable patients. The rate will be reported along with the 95% exact binomial confidence interval. | ClinicalTrials.gov |
| Secondary | Incidence of all-grade immune effector cell associated neurotoxicity syndrome (ICANS) | By day +28 post-CAR T-cell therapy | The occurrence of severe ICANS will be considered binary and the rate will be defined as number of patients with severe ICANS divided by the number of evaluable patients. The rate will be reported along with the 95% exact binomial confidence interval. | ClinicalTrials.gov |
| Secondary | Incidence of disulfiram-related grade 2 to 5 non-hematologic toxicity | By day +28 post-CAR T-cell therapy | Will be assessed by Common Terminology Criteria for Adverse Events, version 5.0. The occurrence of drug related grade 2-5 non-hematologic toxicity with at least a 'possible' attribution to disulfiram will be considered binary, and the rate will be defined as number of patients experiencing toxicity divided by the number of evaluable patients. The rate will be reported along with the 95% exact binomial confidence interval. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)